Moyang Biotechnology is a national-level innovative high-tech enterprise dedicated to the R&D, production, sales, and consulting services of nano medical biomaterials and absorbable Class III implant products. It currently has a complete set of Grade 100 automated filling production equipment, inspection equipment, as well as testing facilities including Grade 10,000 clean rooms, microbiology laboratories, and positive control rooms. At present, the company’s products have obtained product registration certificates issued by the Shanghai Municipal Medical Products Administration and have also obtained the Medical Device Production License. In accordance with market demands and industry development trends, a number of the company’s forward-looking R&D projects have entered the design and development or feasibility demonstration stage. In addition, some of the company’s products have obtained the FSC (Free Sale Certificate) issued by the Shanghai Municipal Medical Products Administration and have entered the international market, currently providing higher-quality treatment methods and care to people pursuing beauty in more than 30 countries around the world.

In June 2023, Nanjing Borui Jiatai Phase II Equity Investment Partnership (Limited Partnership) participated in Moyang Biotechnology’s Series B financing. Established in February 2021, this fund is managed by Borui Yuye (Shanghai) Equity Investment Management Co., Ltd. With a total scale of 150 million yuan, the fund includes a 10 million yuan investment from the Nanjing Industrial Fund, which is entrusted to Nanjing Innovation and Venture Capital Group for management, accounting for 6.67% of the total fund scale. The fund mainly invests in high-quality medical and health industry enterprises with growth potential, covering sectors such as pharmaceutical operations, biotechnology, medical services, medical devices, equipment diagnosis, animal health, and other medical and health-related fields.